Tirzepatide, marketed under the brand name Mounjaro, is a novel medication that combines the effects of GLP-1 and GIP receptor agonists
This helps distinguish the target condition and simplifies insurance billing
Yes, it can happen, but early weight loss is often due to water weight or reduced food volume rather than fat loss
One Mayo Clinic forum discussion acknowledged that an alternating 6-month approach is "creative" and might allow you to get benefits from both while minimizing cumulative side effects
Methods Trial design and participants This phase 3, randomized, double-blind, placebo-controlled study was conducted at 41 sites across five countries (Canada, Italy, Hungary, Spain and the United States), as described in a previous publication 8 and listed in the Supplementary information